Dyne Therapeutics Financial Statements
NASDAQ: DYNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.64+0.27 (+1.65%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dyne Therapeutics revenue and earnings
Dyne Therapeutics reported a net loss of $446.2 million, compared with a loss of $317.4 million a year earlier. Diluted earnings per share came in at -$3.47.
Summary generated from market data by MetaCap's automated system. Methodology
Dyne Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Operating Expenses | 468.18M | 343.89M | 242.16M | 170.96M | 150.03M | 58.65M | 13.83M |
| Research & Development | 398.33M | 281.41M | 210.76M | 142.76M | 121.31M | 45.20M | 11.04M |
| Operating Income | -468.18M | -343.89M | -242.16M | -170.96M | -150.03M | -58.65M | -13.83M |
| Other Income (Expense) | 21.97M | 26.47M | 6.22M | 2.86M | 734.00K | -790.00K | -1.03M |
| Income Tax | 0 | 0 | 0 | — | — | — | — |
| Net Income | -446.21M | -317.42M | -235.94M | -168.10M | -149.29M | -59.44M | -14.86M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | -4.13 | -6.08 |
| EPS (Diluted) | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | -4.13 | -6.08 |
| Shares Outstanding (Basic) | — | — | — | — | 50.90M | 14.40M | 2.44M |
| Shares Outstanding (Diluted) | — | — | — | — | 50.90M | 14.40M | 2.44M |
| EBITDA | -466.13M | -342.21M | -240.49M | -169.28M | -148.94M | -57.95M | -13.55M |
This table shows 7 annual periods of Dyne Therapeutics's income statement, from FY 2025 back to FY 2019, across 11 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow DYN's reporting calendar. What is a income statement?